Results 91 to 100 of about 18,746 (183)
Perifériás markerek jelentősége Alzheimer-kór diagnózisában és terápiájában = Peripheral markers in the diagnosis and the therapy of Alzheimer`s disease [PDF]
, 2006 A legjelentősebb neurokémiai abnormalitás az Alzheimer-kórban (AK) a központi idegrendszer kolinerg rendszerének csökkent működése, de feltehetőleg a perifériás szövetek is érintettek lehetnek.
Kálmán, János, Rakonczay, Zoltán
core
Evaluation of medication treatment for Alzheimer's disease on clinical evidence [PDF]
, 2014 Objective To formulate the best treatment plan for Alzheimer's disease patients by evaluating the therapeutic efficacy and side effect of various evidence-based programs.
Ling LIU +3 more
core +2 more sources
Rivastigmine for the treatment of dementia associated with Parkinson’s disease
Neuropsychiatric Disease and Treatment, 2007 Jennifer L Reingold, John C Morgan, Kapil D SethiMovement Disorders Program, Department of Neurology, Medical College of Georgia, Augusta, GA, USAAbstract: Parkinson’s disease (PD) afflicts millions of people worldwide and leads to cognitive ...
Jennifer L Reingold +2 more
doaj
Tijdschrift voor Gerontologie en GeriatrieCasusbespreking van drie patie¨nten opgenomen in verband met hallucinaties bij de ziekte van Parkinson zonder dementie waarbij naast aanpassing van de anti-parkinson medicatie tevens wordt gestart met rivastigmine waardoor hallucinaties verdwenen en ...
jmp Rovers +2 more
doaj +1 more source
Plants-derived neuroprotective agents: Cutting the cycle of cell death through multiple mechanisms [PDF]
, 2017 Neuroprotection is the preservation of the structure and function of neurons from insults arising from cellular injuries induced by a variety of agents or neurodegenerative diseases (NDs).
Berida, Tomayo Ireti +2 more
core +3 more sources
Behavioural Neurology, 1999 Alzheimer’s disease (AD) is accompanied by prominent behavioural disturbances. They cause significant distress for both caregivers and patients and can play a major role in the decision to institutionalise AD patients.
Michael Rösler +3 more
doaj +1 more source
Is anti-cholinesterase therapy of Alzheimer's disease delaying progression? [PDF]
, 2018 During the last decade, a systematic effort to develop a pharmacological treatment for Alzheimer's disease (AD) resulted in three drugs being registered for the first time in the US and Europe.
Giacobini, E.
core
Dementia & NeuropsychologiaThere is not much published literature on the use of rivastigmine patch in a "routine" clinical setting. Objectives: In this naturalistic longitudinal observational study we sought to evaluate the safety, tolerability and efficacy of the rivastigmine ...
Ejaz Nazir, Muhammad Mushtaq
doaj +1 more source
Experimental pharmacological research regarding some new quinazolin-4-ones derivatives [PDF]
, 2019 A series of new compounds with quinazolin-4-one structure, synthesized by the Pharmaceutical Chemistry Department of the Faculty of Pharmacy of the University of Medicine and Pharmacy “Carol Davila” Bucharest, was studied.
Bratu, Mihaela +8 more
core +1 more source
Clinical Interventions in Aging, 2017 Nagaendran Kandiah,1,2 Ming-Chyi Pai,3,4 Vorapun Senanarong,5 Irene Looi,6,7 Encarnita Ampil,8 Kyung Won Park,9 Ananda Krishna Karanam,10 Stephen Christopher11 1Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, 2Duke-NUS,
Kandiah N +7 more
doaj